PE20211245A1 - Degradadores selectivos del receptor de estrogeno - Google Patents
Degradadores selectivos del receptor de estrogenoInfo
- Publication number
- PE20211245A1 PE20211245A1 PE2021000017A PE2021000017A PE20211245A1 PE 20211245 A1 PE20211245 A1 PE 20211245A1 PE 2021000017 A PE2021000017 A PE 2021000017A PE 2021000017 A PE2021000017 A PE 2021000017A PE 20211245 A1 PE20211245 A1 PE 20211245A1
- Authority
- PE
- Peru
- Prior art keywords
- selective
- receptor degraders
- refers
- compound
- strogen
- Prior art date
Links
- 239000001064 degrader Substances 0.000 title 1
- 150000001875 compounds Chemical class 0.000 abstract 3
- UVBQMXOKKDCBJN-UHFFFAOYSA-N 5-[4-[2-[3-(fluoromethyl)azetidin-1-yl]ethoxy]phenyl]-8-(trifluoromethyl)-5H-chromeno[4,3-c]quinolin-2-ol Chemical compound FCC1CN(C1)CCOC1=CC=C(C=C1)C1OC2=C(C=CC(=C2)C(F)(F)F)C=2C=NC=3C=C(C=CC=3C=21)O UVBQMXOKKDCBJN-UHFFFAOYSA-N 0.000 abstract 1
- 206010006187 Breast cancer Diseases 0.000 abstract 1
- 208000026310 Breast neoplasm Diseases 0.000 abstract 1
- 206010033128 Ovarian cancer Diseases 0.000 abstract 1
- 206010061535 Ovarian neoplasm Diseases 0.000 abstract 1
- 208000005718 Stomach Neoplasms Diseases 0.000 abstract 1
- 229940125641 estrogen receptor degrader Drugs 0.000 abstract 1
- 206010017758 gastric cancer Diseases 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 201000011549 stomach cancer Diseases 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/04—Ortho-condensed systems
- C07D491/044—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
- C07D491/052—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring the oxygen-containing ring being six-membered
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nutrition Science (AREA)
- Physiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Steroid Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Professional, Industrial, Or Sporting Protective Garments (AREA)
- Finger-Pressure Massage (AREA)
- Orthopedics, Nursing, And Contraception (AREA)
Abstract
Referido a un compuesto de formula I, o una sal farmaceuticamente aceptable de este. Estos compuestos son degradadores selectivos del receptor de estrogeno (SERD). Tambien se refiere a una composicion farmaceutica que comprende dicho compuesto; un metodo para preparar 5- (4-{2-[3-(Fluorometil)azetidin-1-il]etoxi}fenil)-8-(trifluorometil)-5H-[1]benzopirano[4,3-c]quinolin-2-ol; y su uso en el tratamiento de cancer de mama, cancer de ovario, cancer gastrico, entre otros.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201862697100P | 2018-07-12 | 2018-07-12 | |
US201962825172P | 2019-03-28 | 2019-03-28 | |
PCT/US2019/041342 WO2020014440A1 (en) | 2018-07-12 | 2019-07-11 | Selective estrogen receptor degraders |
Publications (1)
Publication Number | Publication Date |
---|---|
PE20211245A1 true PE20211245A1 (es) | 2021-07-13 |
Family
ID=67480324
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PE2021000017A PE20211245A1 (es) | 2018-07-12 | 2019-07-11 | Degradadores selectivos del receptor de estrogeno |
Country Status (32)
Country | Link |
---|---|
US (1) | US12128040B2 (es) |
EP (1) | EP3820874B1 (es) |
JP (1) | JP7085056B2 (es) |
KR (1) | KR102577142B1 (es) |
CN (1) | CN112424205B (es) |
AU (1) | AU2019299952B2 (es) |
BR (1) | BR112020025381A2 (es) |
CA (1) | CA3105491C (es) |
CL (1) | CL2021000046A1 (es) |
CO (1) | CO2021000041A2 (es) |
CR (1) | CR20210006A (es) |
DK (1) | DK3820874T3 (es) |
EC (1) | ECSP21001786A (es) |
ES (1) | ES2932867T3 (es) |
FI (1) | FI3820874T3 (es) |
HR (1) | HRP20230080T1 (es) |
HU (1) | HUE061032T2 (es) |
IL (1) | IL279990B2 (es) |
JO (1) | JOP20210004A1 (es) |
LT (1) | LT3820874T (es) |
MD (1) | MD3820874T2 (es) |
MX (1) | MX2021000377A (es) |
PE (1) | PE20211245A1 (es) |
PH (1) | PH12021550048A1 (es) |
PL (1) | PL3820874T3 (es) |
PT (1) | PT3820874T (es) |
RS (1) | RS63876B1 (es) |
SA (1) | SA521421006B1 (es) |
SG (1) | SG11202100145YA (es) |
SI (1) | SI3820874T1 (es) |
UA (1) | UA125890C2 (es) |
WO (1) | WO2020014440A1 (es) |
Families Citing this family (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN108366996B (zh) | 2015-10-01 | 2021-04-09 | 奥列马制药公司 | 四氢-1H-吡啶[3,4-b]吲哚类抗雌激素药物 |
AU2019301679A1 (en) | 2018-07-11 | 2021-01-28 | H. Lee Moffitt Cancer Center And Research Institute, Inc. | Dimeric immuno-modulatory compounds against cereblon-based mechanisms |
TWI702219B (zh) * | 2018-07-12 | 2020-08-21 | 美商美國禮來大藥廠 | 選擇性雌激素受體降解劑 |
TW202300492A (zh) * | 2021-03-16 | 2023-01-01 | 美商美國禮來大藥廠 | 選擇性雌激素受體降解劑 |
EP4361143A4 (en) * | 2021-08-31 | 2025-05-28 | Eisai R&D Management Co., Ltd. | Process for the preparation of a monocyclic pyridine derivative |
EP4472982A1 (en) * | 2022-02-01 | 2024-12-11 | Eli Lilly and Company | Processes for the preparation of selective estrogen receptor degraders |
EP4577533A1 (en) | 2022-08-25 | 2025-07-02 | Sanofi | Novel substituted quinoline and tetrahydronaphthalene carboxylic acid derivatives and therapeutic uses thereof |
Family Cites Families (17)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6756388B1 (en) * | 1993-10-12 | 2004-06-29 | Pfizer Inc. | Benzothiophenes and related compounds as estrogen agonists |
US5521214A (en) * | 1995-01-25 | 1996-05-28 | Eli Lilly And Company | Methods of inhibiting environmental estrogens |
CA2218756A1 (en) * | 1996-10-25 | 1998-04-25 | Kristin Sue Marron | Substituted benzo¢b!thiophene compounds having activity as selective estrogen receptor modulators |
WO2002094788A1 (en) * | 2001-05-22 | 2002-11-28 | Eli Lilly And Company | 2-substituted 1,2,3,4-tetrahydroquinolines and derivatives thereof, compositions and methods |
US7329654B2 (en) * | 2001-12-19 | 2008-02-12 | Janssen Pharmaceutica N.V. | Heteroatom containing tetracyclic derivatives as selective estrogen receptor modulators |
CN100436440C (zh) | 2002-04-19 | 2008-11-26 | 信号药品公司 | 苯并吡喃酮化合物、其组合物以及其治疗方法 |
DE20301728U1 (de) * | 2002-10-11 | 2004-03-11 | Ligand Pharmaceuticals, Inc., San Diego | 5-substituierte 7,9-Difluor-5H-Chromeno(3,4-f) -Chinolin-Verbindungen als selektive Progesteronrezeptormodulator-Verbindungen |
CL2004000985A1 (es) * | 2003-05-16 | 2005-01-14 | Wyeth Corp | Compuestos derivados de fenilquinolinas; composicion farmaceutica, proceso de preparacion; y uso para tratar osteoporosis, enfermedad de paget, dano vascular, osteoartritis, cancer oseo, cancer ovarico, cancer prostatico, hipercolesterolemia, aterosc |
ES2347973T3 (es) | 2004-01-22 | 2010-11-26 | Eli Lilly And Company | Moduladores selectivos de receptor de estrogeno para el tratamiento de sintomas vasomotores. |
AU2005282554A1 (en) * | 2004-09-07 | 2006-03-16 | Wyeth | 6H-[1]benzopyrano[4,3-b]quinolines and their use as estrogenic agents |
US20080221163A1 (en) * | 2005-01-18 | 2008-09-11 | Jeffrey Alan Dodge | Selective Estrogen Receptor Modulators |
CN105451735B (zh) | 2013-06-19 | 2019-01-11 | 西拉根制药公司 | 氮杂环丁烷雌激素受体调节剂和其用途 |
WO2016097071A1 (en) * | 2014-12-18 | 2016-06-23 | F. Hoffmann-La Roche Ag | Estrogen receptor modulators and uses thereof |
EP3303326B1 (en) * | 2015-05-26 | 2020-12-16 | H. Hoffnabb-La Roche Ag | Heterocyclic estrogen receptor modulators and uses thereof |
US9969732B2 (en) * | 2016-04-08 | 2018-05-15 | Genentech, Inc. | Tetrahydroisoquinoline estrogen receptor modulators and uses thereof |
JP7229162B2 (ja) * | 2017-01-06 | 2023-02-27 | ジー1 セラピューティクス, インコーポレイテッド | 癌の治療に対する併用療法 |
TWI702219B (zh) * | 2018-07-12 | 2020-08-21 | 美商美國禮來大藥廠 | 選擇性雌激素受體降解劑 |
-
2019
- 2019-07-11 RS RS20230014A patent/RS63876B1/sr unknown
- 2019-07-11 HR HRP20230080TT patent/HRP20230080T1/hr unknown
- 2019-07-11 UA UAA202100103A patent/UA125890C2/uk unknown
- 2019-07-11 AU AU2019299952A patent/AU2019299952B2/en active Active
- 2019-07-11 PL PL19746252.6T patent/PL3820874T3/pl unknown
- 2019-07-11 SI SI201930407T patent/SI3820874T1/sl unknown
- 2019-07-11 HU HUE19746252A patent/HUE061032T2/hu unknown
- 2019-07-11 KR KR1020217000473A patent/KR102577142B1/ko active Active
- 2019-07-11 FI FIEP19746252.6T patent/FI3820874T3/fi active
- 2019-07-11 BR BR112020025381-2A patent/BR112020025381A2/pt unknown
- 2019-07-11 CN CN201980046170.4A patent/CN112424205B/zh active Active
- 2019-07-11 WO PCT/US2019/041342 patent/WO2020014440A1/en active IP Right Grant
- 2019-07-11 US US17/254,991 patent/US12128040B2/en active Active
- 2019-07-11 MD MDE20210464T patent/MD3820874T2/ro unknown
- 2019-07-11 CR CR20210006A patent/CR20210006A/es unknown
- 2019-07-11 CA CA3105491A patent/CA3105491C/en active Active
- 2019-07-11 PE PE2021000017A patent/PE20211245A1/es unknown
- 2019-07-11 JO JOP/2021/0004A patent/JOP20210004A1/ar unknown
- 2019-07-11 EP EP19746252.6A patent/EP3820874B1/en active Active
- 2019-07-11 SG SG11202100145YA patent/SG11202100145YA/en unknown
- 2019-07-11 MX MX2021000377A patent/MX2021000377A/es unknown
- 2019-07-11 ES ES19746252T patent/ES2932867T3/es active Active
- 2019-07-11 PT PT197462526T patent/PT3820874T/pt unknown
- 2019-07-11 DK DK19746252.6T patent/DK3820874T3/da active
- 2019-07-11 JP JP2021500586A patent/JP7085056B2/ja active Active
- 2019-07-11 LT LTEPPCT/US2019/041342T patent/LT3820874T/lt unknown
-
2021
- 2021-01-06 CO CONC2021/0000041A patent/CO2021000041A2/es unknown
- 2021-01-06 IL IL279990A patent/IL279990B2/en unknown
- 2021-01-07 CL CL2021000046A patent/CL2021000046A1/es unknown
- 2021-01-08 PH PH12021550048A patent/PH12021550048A1/en unknown
- 2021-01-11 EC ECSENADI20211786A patent/ECSP21001786A/es unknown
- 2021-01-12 SA SA521421006A patent/SA521421006B1/ar unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
PE20211245A1 (es) | Degradadores selectivos del receptor de estrogeno | |
CY1122542T1 (el) | Νεα παραγωγα υδροξυεστερα, μια διεργασια για την παρασκευη αυτων και φαρμακευτικες συνθεσεις που περιεχουν αυτα | |
CY1124798T1 (el) | Υποκατεστημενα παραγωγα καρβονουκλεοζιδιων χρησιμα ως παραγοντες κατα των καρκινων | |
PE20191613A1 (es) | Compuestos de pirazolo[1,5-a]piridina sustituidos como inhibidores de la quinasa ret | |
CL2009001065A1 (es) | Compuestos derivados de 4-pirimidinil-1,3-tiazol (o 1,3-oxazol) sulfonamidas sustituidas, inhibidores de quinasas raf; composicion farmaceutica; procedimiento de preparacion; y uso para tratar un neoplasma susceptible, seleccionado de adenocarcinoma de barret, carcinomas del tracto biliar y cancer de seno, entre otros. | |
TN2018000395A1 (en) | New (hetero)aryl-substituted-piperidinyl derivatives, a process for their preparation and pharmaceutical compositions containing them | |
UY29087A1 (es) | Derivados de adamantilo, composiciones farmaceuticas que los contienen, procesos para su preparacion y uso terapeutico | |
AR115694A1 (es) | Degradadores selectivos del receptor de estrógeno | |
AR058389A1 (es) | Uso de derivados heterociclicos benzo-fusionados de sulfamida para el tratamiento de la obesidad | |
MX2018009496A (es) | Degradadores selectivos del receptor de estrogeno y sus usos. | |
UY31215A1 (es) | Compuestos de morfolino pirimidina, procesos para su preparacion, composiciones farmacéuticas conteniéndolos y su uso en terapia. | |
TN2017000524A1 (en) | New bicyclic derivatives, a process for their preparation and pharmaceutical compositions containing them | |
ECSP105253A (es) | Derivados de 5-feniltiazol y uso como inhibidores de pi3 cinasa | |
CL2017001336A1 (es) | Nuevos aminoácidos ester fosforamidatos 2' y/o 5', 3' deoxiadenosina derivativos como compuestos anticancerígenos | |
GT200500119A (es) | Derivados de tetraazabenzo [e] azuleno y sus analogos | |
AR086100A1 (es) | Compuestos de cromenona y composiciones farmaceuticas que los contienen | |
AR081725A1 (es) | Derivados de oxadiazol, proceso de preparacion de los mismos, composicion farmaceutica que los contienen y su uso en el tratamiento del cancer | |
AU2019257509A1 (en) | Androgen receptor modulators and methods for their use | |
DOP2022000066A (es) | Moduladores de sting (estimulador de genes de interferón) | |
DOP2011000283A (es) | Derivados ciclopropil amina | |
EP4286381A3 (en) | Treatment of merkel celll carcinoma | |
BR112019002560A2 (pt) | composto, composição farmacêutica, uso de um composto, e, método | |
CR20210173A (es) | Nuevos derivados amino-pirimidonil-piperidinilo, un proceso para su preparación y composiciones farmacéuticas que los contienen | |
WO2020106751A8 (en) | Inhibitors of gli1 as therapeutic agents | |
NZ741384A (en) | Dopamine d3 receptor antagonists having a morpholine moiety |